通过FGF21-NRF2通路的激活,减轻妊娠糖尿病引起的内皮功能障碍,其中包括L-Cystine
Congcong Sun1, Linlin Wang2, Huiya Huang3
1Department of Scientific Research Center, The Third Affiliated to Shanghai University, Wenzhou People's Hospital, Wenzhou, China.
概括
孕期糖尿病 (GDM) 涉及改变的新陈代谢. 这项研究发现L-Cystine含量升高,并将其与FGF21联系起来,这表明GDM患者的潜在治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 分子生物学分子生物学
背景情况:
- 孕期糖尿病 (GDM) 通过破坏葡萄糖脂类代谢,对母亲和胎儿的健康产生负面影响.
- 关于GDM病原体和有效治疗方法的了解有限.
研究的目的:
- 在GDM患者中识别关键代谢物.
- 探索L-氨酸和纤维细胞生长因子21 (FGF21) 之间的分子相互作用.
- 研究FGF21在GDM中的治疗潜力,专注于内皮功能.
主要方法:
- 来自被诊断患有GDM的孕妇的血清样本使用代谢测序来分析.
- 研究了涉及FGF21,L-Cystine和NRF2的分子相互作用和信号通路.
- 在GDM患者中评估了内皮功能标志物,有或没有运动和饮食干预措施.
主要成果:
- 在GDM患者中发现了升高的L-Cystine水平.
- 在L-Cystine和FGF21水平之间观察到正相关性.
- 发现L-Cystine通过FGF21诱导NRF2表达,在高葡萄糖条件下,通过AKT/IRS1通路上调节内皮保护基因 (NQO1,EPHX1).
- 在GDM患者 (GDM + ED) 的运动和饮食干预改善了FGF21,L-Cystine和内皮功能.
结论:
- 作为GDM的治疗剂,FGF21显得有前途,特别是用于保护内皮细胞.
- 通过生活方式干预来提高L-Cystine可能会增强FGF21在GDM治疗中的疗效.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Pathophysiology of Diabetes
917
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
917
Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Overview of Carbohydrate Metabolism
889
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
889


